Treatment with epigenetic agents potentiates innate and adaptive immune pathways by improving antigen presentation, reexpressing TAAs, upregulating MHC class I and MHC class II, increasing IFN-γ release by tumor-specific CTLs, enhancing the proinflammatory functions of DCs to boost T-cell proliferation and effector T-cell trafficking, and improving the transcriptional activity of some genes related to the immune system, including PD-L1 and genes of the interferon signaling cascade [109]. Here, IFNG is linked to neoplasm.